A team of scientists from Cleveland Clinic’s Lerner Research Institute, Johns Hopkins University School of Medicine and Johns Hopkins Drug Discovery has synthesized and tested a new class of gut-restricted oral therapies that shows promise in treating inflammatory bowel disease.Read More
Researchers have developed a personalized genomic medicine platform to identify clinically actionable mutations and accelerate the development of cancer precision medicine protocols.
Defining the molecular mechanisms that drive the abnormal brain development associated with Zika virus infection.
Researchers have clarified the essential protective role of Β-actin in regulating the epithelial barrier and intestinal inflammation.
Researchers engineer novel disease model to develop new drugs for the treatment of ulcerative colitis. Physician-researcher Emina Huang, MD, explains what makes this model unique.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A new study has identified genetic factors that may influence susceptibility to COVID-19, which could guide personalized treatment. Feixiong Cheng, PhD, explains the implications of his findings.
Researchers demonstrate the value of genetics evaluation and genetic testing in children, adolescents and young adults with solid tumors. Charis Eng, MD, PhD, gives insight into the largest-to-date evaluation of germline mutations in this population.
Traditional methods of drug discovery cannot keep up with the rapid emergence and mutation of human coronavirus epidemics. Feixiong Cheng, PhD, has applied a network-based prediction model to identify targets for drug repurposing for the treatment of COVID-19.
One driver of increased pharmaceutical spending is the high failure rate of expensive and time-consuming randomized control trials. deepDTnet, a network-based deep learning methodology for novel target identification and in silico drug repurposing, may aid in the development of novel, effective treatment strategies for complex diseases.
The association between low lymphocyte levels and reduced survival is strengthened when present in combination with other blood abnormalities. Epidemiologist Jarrod Dalton, PhD, discusses his findings, which suggest that lymphocyte count, red blood cell distribution width and C-reactive protein levels can be used as pragmatic immune status indicators in routine preventive care.
Patterns of miRNA-regulated gene expression may provide insight into disease-disease relationships. Researchers have developed a new analytic tool to predict disease comorbidities based on these miRNA-mediated pathways, which may aid in the development of personalized treatments.